The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 15, 2011, Pages 2403-2410

  Rapkin, Rachel B ^a   Creinin, Mitchell D ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combined oral contraceptive; Drospirenone; Ethinyl estradiol; Folic acid; Levomefolate; Neural tube defect; Oral contraceptive pills

Indexed keywords

CALCIUM DERIVATIVE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL PLUS LEVOMEFOLATE CALCIUM; ETHINYLESTRADIOL; FOLIC ACID; LEVOMEFOLATE CALCIUM; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ACNE VULGARIS; ARTICLE; BLOOD LEVEL; CONTRACEPTION; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; ERYTHROCYTE; FOLIC ACID BLOOD LEVEL; HEADACHE; HUMAN; HYPERKALEMIA; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; MIGRAINE; NAUSEA; NEURAL TUBE DEFECT; PREGNANCY; PREMENSTRUAL DYSPHORIC DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; UTERINE CERVIX CYTOLOGY; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

ANDROSTENES; CALCIUM; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; GLUTAMATES; HUMANS; NEURAL TUBE DEFECTS;

EID: 80052877190     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.610791     Document Type: Article

References (34)

1. U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:626-31
2. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
3. Bachmann G, Sulak P, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 g ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8 (Pubitemid 39119980)
4. Parsey K, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-11 (Pubitemid 30236331)
5. Diefenback K, Trummer D, Ebert F, et al. Changes in folate levels following a 24-week coadministration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg. Eur J Contracept Reprod Health Care 2010;15(Suppl):158-9
6. Diefenbach K, Trummer D, Ebert F, et al. Changes info late levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration. Eur J Contracept Reprod Health Care 2010;15(Suppl):157-8
7. Marr J, Sampson-Landers C, Diefenbach K. Folate and homocysteine levels after 24 weeks administration of YAZ + levomefolate calcium 0.451 mg. Eur J Contracept Reprod Health Care 2010;15(Suppl):159
8. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-17
9. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51 (Pubitemid 26398621)
10. Muhn P, Fuhrmann U, Fritzemeier K, et al. Drospirenone: a Novel Progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35
11. Bachmann G, Sulak P, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 mug ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8 (Pubitemid 39119980)
12. Berlex, Inc.: (drospirenone/ethinyl estradiol/levomefolate calcium) prescribing information. Berlex, Inc., Montvile (NJ) USA (2010). Available from: http://berlex.bayerhealthcare.com/html/products/pi/fhc/Beyaz-PI.pdf
13. Appendix B Criteria sets and axes provided for further study Premenstrual Dysphoric Disorder Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th edition. American Psychiatric Association; Washington, DC: 2000
14. Joffe H, Cohen L, Harlow B. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-30 (Pubitemid 38056418)
15. Yonkers K, Brown C, Pearlstein T, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501 (Pubitemid 41208780)
16. Pearlstein T, Bachmann G, Zacur H, Yonkers K. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21 (Pubitemid 41676830)
17. Maloney JM, Dietze P, Watson D. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. Obstet Gynecol 2008;112:773-80
18. Lucky A, Koltun W, Thiboutot D, et al. A combined oral contraceptive containing 3-mg drospirenone/20-mug ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008;82:143-50
19. CDC Vital Statistics. Use of contraception in the United States: 1982 -2008. U.S. Department of Health and Human Services Center for Disease Control and Prevention National Center for Health Statistics. 2010 Series 23, no 29
20. Mills J, Von Kohorn I, Conley M, et al. Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. Am J Clin Nutr 2003;77:1474-7 (Pubitemid 39655282)
21. Vollset SE, Gjessing HK, Tandbert A, et al. Folate supplementation and twin pregnancies. Epidemiology 2005;16:201-5 (Pubitemid 40314412)
22. Dinger J, Heinemann L, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives base on 142,475 women-years of observation. Contraception 2007;75:344-54 (Pubitemid 46551071)
23. Heinemann L, Dinger J. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75:328-336 (Pubitemid 46551070)
24. Seeger J, Loughlin J, Eng M, et al. Risk of Thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93 (Pubitemid 47359582)
25. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339:b2890
26. Jick S, Hernandez R. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;340:d2151
27. Parkin L, Sharples K, Hernandez R, Jick S. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;340:d2139
28. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 1999;341:709-17 (Pubitemid 29407370)
29. Juulink D, Mamdani M, Lee D, et al. Rates of Hyperkalemia after publication of the randomized aldactone evaluation study. NEJM 2004;351:543-51 (Pubitemid 39025171)
30. Loughlin J, Seeger J, Eng M, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenon and other oral contraceptives. Contraception 2008;78:377-83
31. Schurmann R, Blode H, Benda N, et al. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol 2006;46:867-75 (Pubitemid 44050823)
32. Hatcher R. Contraceptive technology. Ardent Media, Inc; New York: 2007
33. Burris H, Werler M. U.S. provider reported folic acid or multivitamin ordering for non-pregnant women of childbearing age: NAMCS and NHAMCS, 2005-2006. Matern Child Health J 2011;15:352-9
34. ACOG Practice Bulletin. Clinical management guidelines for obstetriciangynecologists. Number 44, July 2003. Obstet Gynecol 2003;102:203-13